Le Lézard
Classified in: Ebola virus, Health
Subject: MISCELLANEOUS

TOMI Environmental Solutions, Inc. Launches "FRST" a Forensic Restoration Service Team, Partnering With The Global BioRisk Advisory Council(GBAC)


BEVERLY HILLS, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® ("TOMI") (OTCQX:TOMZ), a global company that specializes in disinfection and decontamination essentials using its premier Binary Ionization Technology® (BITtm) platform through the manufacturing,  licensing, servicing, and selling of its SteraMisttm brand of products, a hydrogen peroxide-based mist and fog, has launched Forensic Restoration Service Team (FRST), a Crime Clean Network. Members of FRST are trained and certified by the Global BioRisk Advisory Council (GBAC), a TOMI partner comprised of international leaders in the field of microbial ? pathogenic threat analysis, mitigation, response and recovery.

Certified by GBAC, FRST members implement a professional protocol to service and respond to trauma events, efficiently and effectively treating areas, providing options in the aftermath of a tragedy. FRST uses an EPA registered disinfectant, SteraMist by TOMI, to bring homes and business back to normal following all crime scenes including mass casulity, suicide, unattended death, hoarding, biohazard, and/or a variety of other incidents. SteraMist has proven efficacy against a wide range of microorganisms including Ebola, MRSA, C. diff spores, and norovirus, delivering the highest standards in Forensic Restoration®.

GBAC offers a comprehensive certification and training program for biorisk response and management. The certification program is comprised of four tiers to ensure education in responsible biorisk preparation, response and recovery. The next Certified Forensic Operator® Training program will take place on February 5-8, 2019 in Dallas, Texas. Register today.

Dr. Halden Shane, TOMI's CEO, shared, "TOMI is proud to launch its FRST website http://www.crimeclean.com/ for its GBAC certified FRST members and proud to partner with GBAC providing exceptional Forensic Restoration® certification and services, this Crime Clean Network will service Forensic and biohazard Restoration throughout the country, safeguarding the world."

About TOMI Environmental Solutions, Inc.

TOMItm Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BITtm) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BITtm uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (.OH ion), known as ionized Hydrogen Peroxide, iHPtm. Represented by the SteraMisttm brand of products, iHPtm produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hospitality industry, schools, restaurants, food processing facilities, military barracks, police/fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The American Chemical Society, Institute of Electrical and Electronics Engineers, American Seed Trade Association and The Restoration Industry Association.

For additional information, please visit http://www.tomimist.com/ or contact us at [email protected].

About The Global BioRisk Advisory Council (GBAC)  

GBAC is comprised of international leaders in the field of microbial ? pathogenic threat analysis, mitigation, response & recovery, The Global BioRisk Advisory Council (GBAC) provides training, guidance, certification, crisis management, assistance and leadership to government, commercial and private entities looking to mitigate, quickly address biological threats and real-time crises, and/or recover from such events.

For additional information, please visit http://www.gbac.org

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain written and oral statements made by us may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release

INVESTOR RELATIONS CONTACT

Harold Paul
[email protected]


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: